Lucio Catalano
Overview
Explore the profile of Lucio Catalano including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
57
Citations
1459
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Iula R, De Novellis D, Trastulli F, Pepa R, Fontana R, Carobene A, et al.
Front Oncol
. 2022 Dec;
12:1026251.
PMID: 36457484
Belantamab-mafodotin is an innovative and selective treatment for multi-refractory/relapsed multiple myeloma (MM) patients; however, available real-life experiences on efficacy and safety are limited. In this real-world multicentric retrospective study, we...
2.
Morabito F, Zamagni E, Conticello C, Pavone V, Palmieri S, Bringhen S, et al.
Front Oncol
. 2022 Aug;
12:890376.
PMID: 35924160
The present study aimed to develop two survival risk scores (RS) for overall survival (OS, SRS ) and progression-free survival (PFS, PRS ) in 919 relapsed/refractory multiple myeloma (RRMM) patients...
3.
Martino E, Conticello C, Zamagni E, Pavone V, Palmieri S, Musso M, et al.
Hematol Oncol
. 2022 May;
40(5):1009-1019.
PMID: 35638723
In combination with lenalidomide and dexamethasone (KRd), Carfilzomib has been approved for the treatment of relapsed and refractory multiple myeloma (RRMM) on ASPIRE trial. Efficacy and safety of the triplet...
4.
Onder G, Vetrano D, Palmer K, Trevisan C, Amato L, Berti F, et al.
Aging Clin Exp Res
. 2022 Mar;
34(5):989-996.
PMID: 35249211
Multimorbidity and polypharmacy are emerging health priorities and the care of persons with these conditions is complex and challenging. The aim of the present guidelines is to develop recommendations for...
5.
Morabito F, Zamagni E, Conticello C, Pavone V, Palmieri S, Bringhen S, et al.
Eur J Haematol
. 2021 Oct;
108(3):178-189.
PMID: 34716957
The lack of a randomized trial comparing carfilzomib (K) versus elotuzumab (Elo) associated with lenalidomide and dexamethasone (Rd) prompted us to assess the relative usefulness of one triplet over the...
6.
Tacchetti P, Pantani L, Patriarca F, Petrucci M, Zamagni E, Dozza L, et al.
Lancet Haematol
. 2020 Nov;
7(12):e861-e873.
PMID: 33242443
Background: The phase 3 GIMEMA-MMY-3006 trial, which compared bortezomib, thalidomide, and dexamethasone (VTD) combination therapy with thalidomide and dexamethasone (TD) as induction therapy before and consolidation therapy after double autologous...
7.
Fonti R, Pellegrino S, Catalano L, Pane F, Del Vecchio S, Pace L
Ann Hematol
. 2019 Nov;
99(1):127-135.
PMID: 31776725
In multiple myeloma (MM) patients, 18F-FDG-PET/CT allows either the detection of disease spread by using visual parameters based on the Italian Myeloma criteria for PET Use (IMPeTUs) or the direct...
8.
Cerchione C, Martinelli G, Pedatella S, De Nisco M, Pugliese N, Manfra M, et al.
Anticancer Drugs
. 2019 Oct;
31(1):67-72.
PMID: 31633499
Cytarabine, the 4-amino-1-(β-D-arabinofuranosyl)-2(1H)-pyrimidinone, (ARA-C) is an antimetabolite cytidine analogue used worldwide as key drug in the management of leukaemia. As specified in the manufacturers' instructions, once the components-sterile water and...
9.
Cerchione C, De Renzo A, Nappi D, Di Perna M, Pepa R, Pugliese N, et al.
Support Care Cancer
. 2019 Jan;
27(5):1587-1588.
PMID: 30671660
No abstract available.
10.
DAgostino M, De Paoli L, Conticello C, Offidani M, Ria R, Petrucci M, et al.
Crit Rev Oncol Hematol
. 2018 Nov;
132:9-16.
PMID: 30447931
Background: Risk-adapted therapy is a common strategy in curable hematologic malignancies: standard-risk patients receive less intensive treatment, whereas high-risk patients require a more intensive approach. This model cannot be applied...